Patient develops Bio2Skin - Revolutionary medical adhesives for better patient care

Frequent and continuous usage of medical devices (MD) attached to the skin often causes severe skin injuries to the patient known as MARSI (Medical Adhesive-Related Skin Injuries) due to the aggressive peeling of the current medical adhesives that are vicious, chemical and glue-based materials. MARSI occur when the attachment of an adhesive to the skin is stronger than the attachment between skin cells. Any patient who uses a medical dressing/device can potentially experience MARSI, however certain groups are more vulnerable, for example, infants, elderly patients, oncology, orthopedic surgery, and ostomate patients. Namely, 1 in 5 of hospitalized infants and children, 1 in 5 long-term care patients, 2 in 5 hip surgery patients, and 4 in 5 ostomate patients suffer because of MARSI.

To solve this, Sónia founded BestHealth4U in 2017and created Bio2Skin: a novel glue-less adhesive solution for medical applications.
Bio2Skin was developed to positively impact the health and daily routine of patients that have medical devices attached to their skin as part of treatment. It avoids skin injury in prolonged use or upon removal. Bio2Skin has a combination of highly biocompatible polymers that respect the skin, avoiding irritation and allergic reactions even under continuous use. Bio2Skin is a bio-based medical adhesive that disrupts the current concept of adhesives as it is glue-less and doesn't "stick" to the skin.
Bio2Skin uses the natural features of the skin to establish adhesion through water molecules, thus providing a strong, safe, and gentle adhesive solution for a wide range of MD, including, tapes and wound dressings, attachment of critical tubes, access devices, and ostomy products, electronic wearables, transdermal delivery skin-patches, etc.

Due to the multi-dynamic and multi-applicability of Bio2Skin's material, BestHealth4U has been exploring it in several new products and applications, namely in the digital medical monitoring and applications of transdermal drug delivery through the skin.

Bio2Skin is fully developed having achieved proof-of-concept in 2018, and in early 2019, Bio2Skin achieved TRL6 with remarkable mechanical tests and promising pre-clinical studies. Currently, Bio2Skin is under biocompatibility certification, ISO 10993, being necessary for its commercialization. In 2019, BH4U started commercialization relationships with several MedTech companies, where they are testing Bio2Skin and applying it to their own medical products. So far, BestHealth4U has raised €600k in grants, prizes, and awards that have provided the current technological advances.

Adapted from: https://besthealth4u.pt/home/, https://www.xeurope.eu/post/besthealth4u-x-europe-startup-interview
https://vimeo.com/517216125